Pre-exposure prophylaxis of HIV

Pre-Exposure Prophylaxis for HIV Prevention.

c ase vignet tes The first patient, a 46-year-old sexually active man who has sex with men, presents for routine primary care. He lives in New York City and reports that he is in a long-term, stable, open relationship with a male partner and that he has had multiple recent sexual encounters with acquaintances. A recent HIV test was negative. He has seasonal allergies, for which he occasionally ...

HIV pre-exposure prophylaxis for women

Women and girls comprise nearly half of HIV-infected individuals globally and 20% of new infections in the United States, indicating an urgent need to optimise HIV prevention options in this population. HIV pre-exposure prophylaxis (PrEP) - where antiretrovirals are administered to HIV-non-infected individuals at risk of HIV acquisition - is a promising, female-controlled HIV prevention strateg...

A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective

When taken consistently, pre-exposure prophylaxis (PrEP) against human immunodeficiency virus (HIV) with once daily tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) has been shown to safely reduce the incidence of HIV infection in high-risk individuals by more than 90%. Yet, according to the Centers for Disease Control and Prevention, there were about 2.1 million new cases of HIV reported ...

Predicting effect of pre-exposure prophylaxis on HIV epidemics.

We agree with Angela Kashuba and colleagues (June 30, p 2409) that it is essential to develop new methods for measuring adherence to preexposure prophylaxis (PrEP) for HIV prevention in clinical trials. However, another important issue also needs to be addressed. Specifi cally, how can adherence data from clinical trials be interpreted and used to predict the success of PrEP in reducing transmi...

Perspectives of women prescribed HIV pre-exposure prophylaxis (PrEP)